Renalytix PLC Issue of shares and Total Voting Rights (9254Q)
01 Noviembre 2021 - 6:00AM
UK Regulatory
TIDMRENX
RNS Number : 9254Q
Renalytix PLC
01 November 2021
Renalytix plc
("Renalytix" or the "Company")
Issue of shares and Total Voting Rights
NEW YORK, November 1, 2021 - Renalytix plc (AIM: RENX) announces
that it has issued and allotted 68,224 ordinary shares of 0.25
pence each in the share capital of the Company ("Ordinary Shares")
following an exercise of options on 29 October 2021. The exercise
price was 121 pence per Ordinary Share.
Application has been made to the London Stock Exchange for the
new Ordinary Shares to be admitted to trading on AIM. It is
expected that admission of the 68,224 new Ordinary Shares to
trading on AIM will become effective on, or around, 5 November 2021
("Admission").
Total voting rights
Following Admission, the Company will have 72,308,930 Ordinary
Shares in issue with each share carrying the right to one vote. The
Company has no Ordinary Shares held in treasury. The total number
of voting rights in the Company following Admission will therefore
be 72,308,930.
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About KidneyIntelX
KidneyIntelX is a first-of-kind solution that enables
early-stage diabetic kidney disease (DKD) progression risk
assessment by combining diverse data inputs, including validated
blood-based biomarkers, inherited genetics, and personalized
patient data from electronic health record systems, and employs a
proprietary algorithm to generate a unique patient risk score. This
patient risk score enables prediction of progressive kidney
function decline in chronic kidney disease, allowing physicians and
healthcare systems to optimize the allocation of treatments and
clinical resources to patients at highest risk.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and
leader in the new field of bioprognosis(TM) for kidney health. The
company has engineered a new solution that successfully enables
early-stage chronic kidney disease, progression risk assessment.
The Company's lead product, KidneyIntelX, has been granted
Breakthrough Designation by the U.S. Food and Drug Administration
and is designed to help make significant improvements in kidney
disease prognosis, transplant management, clinical care, patient
stratification for drug clinical trials, and drug target discovery
(visit www.kidneyintelx.com ). For more information, visit
www.renalytix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDKDBPDBDDCDK
(END) Dow Jones Newswires
November 01, 2021 08:00 ET (12:00 GMT)
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
